Last updated: March 26, 2024
Sponsor: Pfizer
Overall Status: Trial Not Available
Phase
N/A
Condition
Covid-19
Treatment
Nirmatrelvir/Ritonavir
Clinical Study ID
NCT05997485
C4671060
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Confirmed COVID-19 infection during the study period from 01 June 2022 to 30 June 2023
- Nirmatrelvir, ritonavir written prescription
Exclusion
Exclusion Criteria:
- There are no exclusion criteria for this study.
Study Design
Treatment Group(s): 1
Primary Treatment: Nirmatrelvir/Ritonavir
Phase:
Study Start date:
March 30, 2024
Estimated Completion Date:
June 30, 2024